Primary Job Title Founder Primary Organization 
Synthorx
Location United States, North America Gender Male
Floyd E. Romesberg, Ph.D. is the scientific founder and a member of the board of directors of Synthorx. Prior to Synthorx, he served as the scientific co-founder and a member of the board of directors of RQx Pharmaceuticals (acquired by Genentech) and Achaogen, two biopharmaceutical companies focused on developing new antibiotics. Floyd Romesberg
is also an associate professor of chemistry at The Scripps Research Institute. His academic research laboratory uses a broad range of interdisciplinary techniques, including non-linear optical spectroscopy, organic chemistry, microbiology, and genetics, to study different aspects of evolution. This work has been described in more than 100 peer-reviewed publications and has been funded by the National Institutes of Health, National Science Foundation, and Office of Naval Research. Floyd Romesberg is best known for developing unnatural base pairs for the expansion of the genetic alphabet and is also working to develop novel antibiotics, as well as to understand how evolution tailors protein dynamics and how cellular stress and DNA damage induce cell-cycle checkpoint responses and mutations. Floyd Romesberg performed his postdoctoral training with Dr. Peter Schultz at the University of California, Berkeley. He received a Ph.D. in physical organic chemistry from Cornell University and a B.S. in chemistry from The Ohio State University.
